Nexalin Technology (NXL) said Monday it secured a patent for its deep intracranial frequency stimulation technology in treating substance use disorders.
The firm said the US Patent and Trademark Office granted its patent "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder."
The technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway, Nexalin said.
Price: 1.97, Change: +0.08, Percent Change: +4.23